https://scholars.lib.ntu.edu.tw/handle/123456789/108182
DC Field | Value | Language |
---|---|---|
dc.contributor | 公共衛生學系;Department of Public Health | en |
dc.contributor.author | CHANG, HUI-JU | en |
dc.contributor.author | WANG, CHUAN-CHENG | en |
dc.contributor.author | CHENG, ANN-LII | en |
dc.contributor.author | 張俊彥 | zh-tw |
dc.creator | CHANG, HUI-JU;WANG, CHUAN-CHENG;CHENG, ANN-LII;HSU, CHIUN;LU, YEN-SHEN;CHANG, MING-CHU;LIN, JAW-TOWN;WANG, HSIU-PO;LIU, TSANG-WU;CHANG, JANG-YANG;WHANG-PENG, JACQUELINE;CHEN, LI-TZONG | en |
dc.creator | 張慧如;王全正;鄭安理;許駿;盧彥伸;章明珠;林肇堂;王秀伯;劉滄梧;張俊彥;彭汪嘉康;陳立宗 | zh-tw |
dc.date | 2006 | en |
dc.date.accessioned | 2008-07-30T06:16:46Z | - |
dc.date.accessioned | 2018-06-29T16:31:05Z | - |
dc.date.available | 2008-07-30T06:16:46Z | - |
dc.date.available | 2018-06-29T16:31:05Z | - |
dc.date.issued | 2006 | - |
dc.identifier.uri | http://ntur.lib.ntu.edu.tw//handle/246246/80940 | - |
dc.description.abstract | Objectives: To evaluate the feasibility and maximal tolerated dose (MTD) of oxaliplatin of a triplet regimen consisting of gemcitabine, oxaliplatin and infusional fluorouracil (5-FU)/leucovorin (LV) (GOFL) for advanced pancreatic cancer. Patients and Methods: Patients with histologically proven metastatic or unresectable, locally advanced pancreatic adenocarcinoma were eligible to take part in the study. The treatment consisted of fixed-rate infusion (10 mg/m(2)/minute) of 800 mg/m(2) gemcitabine followed by 2-h infusion of oxaliplatin and then 48-h infusion of 5-FU/LV day 1 and day 15 every 4 weeks. The oxaliplatin would be evaluated at three dose levels, 65, 75 and 85 mg/m(2). Results: A total of 15 patients were enrolled at three dose levels. Dose-limiting toxicity of neutropenic fever and grade 4 thrombocytopenia occurred in one of each six patients at oxaliplatin dose level of 65 mg/ m(2) and 85 mg/m(2), respectively. The MTD of oxaliplatin for this combination was 85 mg/m(2). After a median four cycles of treatment, grade 3/4 neutropenia occurred in 46.7% of patients and thrombocytopenia in 13.3%. Non- hematological toxicities were generally of grade 1/2. Objective tumor response was observed in five patients (33.3 %, 95% confidence interval, 6.3-60.4%). Conclusion: Biweekly GOFL is a feasible regimen for advanced pancreatic cancer. For further phase II studies, the recommended dose of oxaliplatin is 85 mg/m(2). | en |
dc.language | en-us | en |
dc.language.iso | en_US | - |
dc.relation | J GASTROENTEROL HEPATOL v.21 n.5 pp.874-879 | en |
dc.relation.ispartof | J GASTROENTEROL HEPATOL | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.title | PHASE I STUDY OF BIWEEKLY GEMCITABINE FOLLOWED BY OXALIPLATIN AND SIMPLIFIED 48-H INFUSION OF FLUOROURACIL/LEUCOVORIN FOR ADVANCED PANCREATIC CANCER | en |
dc.type | journal article | en |
dc.relation.pages | 874-879 | - |
dc.relation.journalvolume | v.21 | - |
dc.relation.journalissue | n.5 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.fulltext | no fulltext | - |
item.cerifentitytype | Publications | - |
item.languageiso639-1 | en_US | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
Appears in Collections: | 公共衛生學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.